Evaluation of DNA methylation in BDNF, SLC6A4, NR3C1 and FKBP5 before and after treatment with selective serotonin-reuptake inhibitor in major depressive disorder

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Hardeveld F, Spijker J, De Graaf R, Nolen W, Beekman A. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr. Scand. 122(3), 184–191 (2010).
  Medline CASGoogle Scholar
• 2. Clark SL, Hattab MW, Chan RF et al. A methylation study of long-term depression risk. Mol. Psychiatry 25(6), 1334–1343 (2020).
  Medline CASGoogle Scholar
• 3. Frokjaer VG. Pharmacological sex hormone manipulation as a risk model for depression. J. Neurosci. Res. 98(7), 1283–1292 (2020).
  Medline CASGoogle Scholar
• 4. Gharraee B, Tajrishi KZ, Sheybani F et al. Prevalence of major depressive disorder in the general population of Iran: a systematic review and meta-analysis. Med. J. Islam. Repub. Iran 33, 151 (2019).
  MedlineGoogle Scholar
• 5. Lee M-S. Pharmacogenetic treatment of depressive disorders Future Neurol. 2(3), 329–338 2007).
  CASGoogle Scholar
• 6. Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S. Prognosis and improved outcomes in major depression: a review. Transl. Psychiatry 9(1), 127 (2019).
  MedlineGoogle Scholar
• 7. Bialek K, Czarny P, Strycharz J, Sliwinski T. Major depressive disorders accompanying autoimmune diseases – response to treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 95 109678 (2019).
  MedlineGoogle Scholar
• 8. Mullins CD, Shaya FT, Meng F, Wang J, Harrison D. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram. Pharmacotherapy 25(5), 660–667 (2005). • Epigenetic changes are involved in the progression and treatment of depression.
  MedlineGoogle Scholar
• 9. Lozupone M, Panza F. Social determinants of late-life depression epigenetics. Epigenomics 12(7), 559–562 (2020).
  CASGoogle Scholar
• 10. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J. Toxicol. Clin. Toxicol. 42(3), 277–285 (2004).
  Medline CASGoogle Scholar
• 11. Narasimhan S, Lohoff FW. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics 13(4), 441–464 (2012).
  CASGoogle Scholar
• 12. Hyttel J,Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9( Suppl. 1),19–26( 1994).
  MedlineGoogle Scholar
• 13. Reynolds GP, Fachim HA. Does DNA methylation influence the effects of psychiatric drugs? Epigenomics 8(3), 309–312 (2016).
  CASGoogle Scholar
• 14. Tsai S-J, Hong C-J, Liou Y-J. Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics. Pharmacogenomics 9(9),1353–1358( 2008).
  CASGoogle Scholar
• 15. García-Marín LM, Rabinowitz JA, Ceja Z, Alcauter S, Medina-Rivera A, Rentería ME. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics 4, 233–244( 2022).
  Google Scholar
• 16. Czarny P, Białek K, Ziółkowska S, Strycharz J, Barszczewska G, Sliwinski T. The importance of epigenetics in diagnostics and treatment of major depressive disorder. J. Pers. Med. 11(3), 167 (2021).
  MedlineGoogle Scholar
• 17. Zhou J, Li M, Wang X et al. Drug response-related DNA methylation changes in schizophrenia, bipolar disorder, and major depressive disorder. Front. Neurosci. 15, 674273( 2021).
  MedlineGoogle Scholar
• 18. Kimmel M, Kaminsky Z, Payne JL. Biomarker or pathophysiology? The role of DNA methylation in postpartum depression. Epigenomics 5(5), 473–475 (2013).
  CASGoogle Scholar
• 19. Volkow ND, Koob G, Baler R. Biomarkers in substance use disorders. ACS Chem. Neurosci. 6(4), 522–525 (2015).
  Medline CASGoogle Scholar
• 20. Dereix AE, Ledyard R, Redhunt AM et al. Maternal anxiety and depression in pregnancy and DNA methylation of the NR3C1 glucocorticoid receptor gene. Epigenomics 13(21), 1701–1709 (2021).
  CASGoogle Scholar
• 21. Shields AE, Wise LA, Ruiz-Narvaez EA et al. Childhood abuse, promoter methylation of leukocyte NR3C1 and the potential modifying effect of emotional support. Epigenomics 8(11), 1507–1517 (2016).
  CASGoogle Scholar
• 22. Nagarajan S, Seddighzadeh B, Baccarelli A, Wise LA, Williams M, Shields AE. Adverse maternal exposures, methylation of glucocorticoid-related genes and perinatal outcomes: a systematic review. Epigenomics 8(7), 925–944 (2016).
  CASGoogle Scholar
• 23. Winkler BK, Lehnert H, Oster H, Kirchner H, Harbeck B. FKBP5 methylation as a possible marker for cortisol state and transient cortisol exposure in healthy human subjects. Epigenomics 9(10), 1279–1286 (2017).
  CASGoogle Scholar
• 24. Montirosso R, Provenzi L, Giorda R et al. SLC6A4 promoter region methylation and socio-emotional stress response in very preterm and full-term infants. Epigenomics 8(7), 895–907 (2016).
  CASGoogle Scholar
• 25. Park C, Rosenblat JD, Brietzke E et al. Stress, epigenetics and depression: a systematic review. Neurosci. Biobehav. Rev. 102, 139–152 (2019).
  Medline CASGoogle Scholar
• 26. Iamjan S-A, Thanoi S, Watiktinkorn P et al. Changes of BDNF exon IV DNA methylation are associated with methamphetamine dependence. Epigenomics 13(12), 953–965 (2021).
  CASGoogle Scholar
• 27. Scharinger C, Bartova L, Pezawas L. Brain-derived neurotrophic factor: a peripheral biomarker for major depressive disorder and antidepressant efficacy? Per. Med. 8(2), 115–117 (2011).
  CASGoogle Scholar
• 28. Ahmadimanesh M, Abbaszadegan MR, Rad DM et al. Effects of selective serotonin reuptake inhibitors on DNA damage in patients with depression. J. Psychopharmacol. 33(11), 1364–1376 (2019).
  Medline CASGoogle Scholar
• 29. Switzeny OJ, Christmann M, Renovanz M, Giese A, Sommer C, Kaina B. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Clin. Epigenetics 8(1), 1–10 (2016).
  MedlineGoogle Scholar
• 30. Nourian YH, Beh-Pajooh A, Aliomrani M et al. Changes in DNA methylation in APOE and ACKR3 genes in multiple sclerosis patients and the relationship with their heavy metal blood levels. Neurotoxicology 87, 182–187 (2021).
  MedlineGoogle Scholar
• 31. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H. BDNF function and intracellular signaling in neurons. Histol. Histopathol. 25, 237–258(2010).
  Medline CASGoogle Scholar
• 32. Stein DJ, Daniels WM, Savitz J, Harvey BH. Brain-derived neurotrophic factor: the neurotrophin hypothesis of psychopathology. CNS Spectr. 13(11), 945–949 (2008).
  MedlineGoogle Scholar
• 33. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev. Neurobiol. 70(5), 289–297 (2010).
  Medline CASGoogle Scholar
• 34. Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse and rat BDNF gene structure and expression revisited. J. Neurosci. Res. 85(3), 525–535 (2007).
  Medline CASGoogle Scholar
• 35. Martinowich K, Hattori D, Wu H et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302(5646), 890–893 (2003). •• Among depressed individuals, DNA methylation is higher in the BDNF promoter.
  Medline CASGoogle Scholar
• 36. Fuchikami M, Morinobu S, Segawa M et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLOS ONE 6(8), e23881 (2011).
  Medline CASGoogle Scholar
• 37. Tadić A, Müller-Engling L, Schlicht K et al. Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Mol. Psychiatry 19(3), 281–283 (2014).
  Medline CASGoogle Scholar
• 38. Chen D, Meng L, Pei F, Zheng Y, Leng J. A review of DNA methylation in depression. J. Clin. Neurosci. 43, 39–46 (2017). •• DNA methylation changes in BDNF gene in response to paroxetine treatment.
  Medline CASGoogle Scholar
• 39. Gassen NC, Fries GR, Zannas AS et al. Chaperoning epigenetics: FKBP51 decreases the activity of DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. Sci. Signal. 8(404), ra119 (2015).
  MedlineGoogle Scholar
• 40. Melas PA, Rogdaki M, Lennartsson A et al. Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int. J. Neuropsychopharmacol. 15(5), 669–679 (2012).
  Medline CASGoogle Scholar
• 41. Zhang Y, Gu F, Chen J, Dong W. Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res. 1366, 141–148 (2010).
  Medline CASGoogle Scholar
• 42. Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP. Physical activity–antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav. Brain Res. 120(1), 87–95 (2001).
  Medline CASGoogle Scholar
• 43. Turner JD, Alt SR, Cao L et al. Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more. Biochem. Pharmacol. 80(12), 1860–1868 (2010). •• NR3C1 methylation of DNA increases in infants of depressed mothers.
  Medline CASGoogle Scholar
• 44. Murgatroyd C, Quinn J, Sharp H, Pickles A, Hill J. Effects of prenatal and postnatal depression, and maternal stroking, at the glucocorticoid receptor gene. Transl. Psychiatry 5(5), e560 (2015).
  Medline CASGoogle Scholar
• 45. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 3(2), 97–106 (2008).
  MedlineGoogle Scholar
• 46. Luddington NS, Mandadapu A, Husk M, El-Mallakh RS. Clinical implications of genetic variation in the serotonin transporter promoter region: a review. Prim. Care Companion J. Clin. Psychiatry 11(3), 93 (2009).
  MedlineGoogle Scholar
• 47. Webb LM, Phillips KE, Ho MC, Veldic M, Blacker CJ. The relationship between DNA methylation and antidepressant medications: a systematic review. Int. J. Mol. Sci. 21(3), 826 (2020).
  Medline CASGoogle Scholar
• 48. Philibert R, Madan A, Andersen A, Cadoret R, Packer H, Sandhu H. Serotonin transporter mRNA levels are associated with the methylation of an upstream CpG island. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144(1), 101–105 (2007).
  Google Scholar
• 49. Olsson C, Foley D, Parkinson-Bates M et al. Prospects for epigenetic research within cohort studies of psychological disorder: a pilot investigation of a peripheral cell marker of epigenetic risk for depression. Biol. Psychol. 83(2), 159–165 (2010).
  Medline CASGoogle Scholar
• 50. Gaspar P, Cases O, Maroteaux L. The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 4(12), 1002–1012 (2003).
  Medline CASGoogle Scholar
• 51. Schiele MA, Zwanzger P, Schwarte K, Arolt V, Baune BT, Domschke K. Serotonin transporter gene promoter hypomethylation as a predictor of antidepressant treatment response in major depression: a replication study. Int. J. Neuropsychopharmacol. 24(3), 191–199 (2021).
  Medline CASGoogle Scholar
• 52. Wang Q, Shelton RC, Dwivedi Y. Interaction between early-life stress and FKBP5 gene variants in major depressive disorder and post-traumatic stress disorder: a systematic review and meta-analysis. J. Affect. Disord. 225, 422–428 (2018).
  Medline CASGoogle Scholar
• 53. Zannas AS, Wiechmann T, Gassen NC, Binder EB. Gene–stress–epigenetic regulation of FKBP5: clinical and translational implications. Neuropsychopharmacology 41(1), 261–274 (2016). •• DNA methylation in the glucocorticoid receptor (GR) system is associated with depression.
  Medline CASGoogle Scholar
• 54. Höhne N, Poidinger M, Merz F et al. FKBP5 genotype-dependent DNA methylation and mRNA regulation after psychosocial stress in remitted depression and healthy controls. Int. J. Neuropsychopharmacol. 18(4), pyu087 (2015).
  Google Scholar
• 55. Weder N, Zhang H, Jensen K et al. Child abuse, depression, and methylation in genes involved with stress, neural plasticity, and brain circuitry. J. Am. Acad. Child Adolesc. Psychiatry 53(4), 417–424.e5 (2014).
  MedlineGoogle Scholar
• 56. Klinger-König J, Hertel J, Van der Auwera S et al. Methylation of the FKBP5 gene in association with FKBP5 genotypes, childhood maltreatment and depression. Neuropsychopharmacology 44(5), 930–938 (2019).
  MedlineGoogle Scholar
• 57. Miller O, Shakespeare-Finch J, Bruenig D, Mehta D. DNA methylation of NR3C1 and FKBP5 is associated with posttraumatic stress disorder, posttraumatic growth, and resilience. Psychol. Trauma 12(7), 750 (2020).
  MedlineGoogle Scholar
• 58. Matosin N, Halldorsdottir T, Binder EB. Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: the FKBP5 model. Biol. Psychiatry 83(10), 821–830 (2018).
  Medline CASGoogle Scholar
• 59. Yehuda R, Daskalakis NP, Desarnaud F et al. Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD. Front. Psychiatry 4(118), (2013).
  MedlineGoogle Scholar
• 60. Lopez J, Mamdani F, Labonte B et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol. Psychiatry 18(4), 398–399 (2013).
  Medline CASGoogle Scholar
• 61. Okada S, Morinobu S, Fuchikami M et al. The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression. J. Psychiatr. Res. 53, 47–53 (2014).
  MedlineGoogle Scholar